September 27, 2016
A systematic analysis of studies examining the impacts on antiretroviral treatment goals of access to opioid substitution therapy in HIV care settings for people who inject drugs, found improved outcomes on treatment initiation, retention, and effectiveness, an article in Clinical Infectious Diseases released this week says.
The one exception to a pattern of benefits accruing from medication-assisted therapy for opioid dependence included in treatment for people who inject drugs and are living with HIV, demonstrated across the studies was a reduction in mortality, with only one study examining and confirming a reduction in HIV-related mortality, and others not finding a link between the services and drops in all cause mortality.
The authors of the study combed through 3558 studies, to find 32 that met the criteria of describing impacts of opioid substitution therapy on HIV program objectives that included antiretroviral treatment recruitment, adherence, and viral suppression among people who inject drugs. Examining studies of services to more than 36,000 people in 9 countries between 1996 and 2014, they found access to the therapy increased rates of antiretroviral treatment coverage among people who inject drugs by 54 percent, increased treatment enrollment by 87 percent, doubled rates of adherence to treatment, and increased rates of viral suppression by 45 percent.
This excerpt was cross-posted with the permission of Science Speaks. Read the full article.
|For Injection Drug Users With HIV, Higher Risk of Liver/Kidney Disease -- But Not Other Non-AIDS Ills|
|Staying Safe: What People Who Inject Drugs Know About Preventing Hep C and HIV|
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.